How much did Affimed achieve in EBIT for the current year?
In the current year, Affimed has achieved an EBIT of -65.13 M EUR.
Affimed EBIT 2024
Affimed EBIT
-65.13 M EUR
Ticker
AFMD
ISIN
NL0010872420
WKN
A12BHU
In 2024, Affimed's EBIT was -65.13 M EUR, a -39.47% increase from the -107.6 M EUR EBIT recorded in the previous year.
The Affimed EBIT history
| YEAR | EBIT (undefined EUR) |
|---|---|
| 2029e | - |
| 2028e | - |
| 2027e | - |
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
Affimed Revenue, EBIT, Net Income NL0010872420 · A12BHU
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Affimed, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Affimed from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Affimed’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Affimed. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Affimed’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Affimed’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Affimed’s growth potential.
Affimed Revenue, EBIT and net profit per share
| Date | Affimed Revenue | Affimed EBIT | Affimed Net Income |
|---|---|---|---|
| 2029e | 179.09 M undefined | -27.61 M undefined | -10.95 M undefined |
| 2028e | 74.06 M undefined | -104.3 M undefined | -31.97 M undefined |
| 2027e | 13.91 M undefined | -138.49 M undefined | -41.67 M undefined |
| 2026e | 11.77 M undefined | -105.06 M undefined | -37.35 M undefined |
| 2025e | 4.99 M undefined | -74.52 M undefined | -37.41 M undefined |
| 2024e | 2.28 M undefined | -65.13 M undefined | -60.87 M undefined |
| 2023 | 8.28 M undefined | -107.6 M undefined | -105.94 M undefined |
| 2022 | 41.35 M undefined | -88.22 M undefined | -86 M undefined |
| 2021 | 40.37 M undefined | -64.16 M undefined | -57.52 M undefined |
| 2020 | 28.36 M undefined | -34.85 M undefined | -41.37 M undefined |
| 2019 | 21.39 M undefined | -32.63 M undefined | -32.37 M undefined |
| 2018 | 23.74 M undefined | -21.06 M undefined | -19.48 M undefined |
| 2017 | 2.01 M undefined | -27.26 M undefined | -30.22 M undefined |
| 2016 | 6.31 M undefined | -32.04 M undefined | -32.22 M undefined |
| 2015 | 7.56 M undefined | -21.34 M undefined | -20.24 M undefined |
| 2014 | 3.38 M undefined | -8.18 M undefined | -259,000 undefined |
| 2013 | 5.09 M undefined | -15.7 M undefined | -26.1 M undefined |
| 2012 | 1.17 M undefined | -10.4 M undefined | -14.31 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2012 | 1.17 M EUR | -10.4 M EUR | -14.31 M EUR |
| 2013 | 5.09 M EUR | -15.7 M EUR | -26.1 M EUR |
| 2014 | 3.38 M EUR | -8.18 M EUR | -259,000 EUR |
| 2015 | 7.56 M EUR | -21.34 M EUR | -20.24 M EUR |
| 2016 | 6.31 M EUR | -32.04 M EUR | -32.22 M EUR |
| 2017 | 2.01 M EUR | -27.26 M EUR | -30.22 M EUR |
| 2018 | 23.74 M EUR | -21.06 M EUR | -19.48 M EUR |
| 2019 | 21.39 M EUR | -32.63 M EUR | -32.37 M EUR |
| 2020 | 28.36 M EUR | -34.85 M EUR | -41.37 M EUR |
| 2021 | 40.37 M EUR | -64.16 M EUR | -57.52 M EUR |
| 2022 | 41.35 M EUR | -88.22 M EUR | -86 M EUR |
| 2023 | 8.28 M EUR | -107.6 M EUR | -105.94 M EUR |
| 2024e | 2.28 M EUR | -65.13 M EUR | -60.87 M EUR |
| 2025e | 4.99 M EUR | -74.52 M EUR | -37.41 M EUR |
| 2026e | 11.77 M EUR | -105.06 M EUR | -37.35 M EUR |
| 2027e | 13.91 M EUR | -138.49 M EUR | -41.67 M EUR |
| 2028e | 74.06 M EUR | -104.3 M EUR | -31.97 M EUR |
| 2029e | 179.09 M EUR | -27.61 M EUR | -10.95 M EUR |
Affimed stock margins NL0010872420 · A12BHU
The Affimed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Affimed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Affimed.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Affimed's sales revenue. A higher gross margin percentage indicates that the Affimed retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Affimed's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Affimed's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Affimed's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Affimed. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Affimed's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Affimed Margin History
| Affimed Gross margin | Affimed Profit margin | Affimed EBIT margin | Affimed Profit margin |
|---|---|---|---|
| 2029e | 83.7 % | -15.42 % | -6.11 % |
| 2028e | 83.7 % | -140.84 % | -43.17 % |
| 2027e | 83.7 % | -995.56 % | -299.57 % |
| 2026e | 83.7 % | -892.56 % | -317.26 % |
| 2025e | 83.7 % | -1,492.75 % | -749.45 % |
| 2024e | 83.7 % | -2,854.09 % | -2,667.55 % |
| 2023 | 83.7 % | -1,300.34 % | -1,280.22 % |
| 2022 | 94.83 % | -213.33 % | -207.98 % |
| 2021 | 94.67 % | -158.93 % | -142.5 % |
| 2020 | 93.9 % | -122.87 % | -145.86 % |
| 2019 | 92.77 % | -152.53 % | -151.3 % |
| 2018 | 95.2 % | -88.73 % | -82.06 % |
| 2017 | 50.55 % | -1,356.22 % | -1,503.63 % |
| 2016 | 83.72 % | -507.51 % | -510.23 % |
| 2015 | 88.07 % | -282.24 % | -267.64 % |
| 2014 | 75.04 % | -241.81 % | -7.66 % |
| 2013 | 86.06 % | -308.69 % | -513.05 % |
| 2012 | 53.11 % | -886.36 % | -1,220.29 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2012 | 53.11 % | -886.36 % | -1,220.29 % |
| 2013 | 86.06 % | -308.69 % | -513.05 % |
| 2014 | 75.04 % | -241.81 % | -7.66 % |
| 2015 | 88.07 % | -282.24 % | -267.64 % |
| 2016 | 83.72 % | -507.51 % | -510.23 % |
| 2017 | 50.55 % | -1,356.22 % | -1,503.63 % |
| 2018 | 95.2 % | -88.73 % | -82.06 % |
| 2019 | 92.77 % | -152.53 % | -151.3 % |
| 2020 | 93.9 % | -122.87 % | -145.86 % |
| 2021 | 94.67 % | -158.93 % | -142.5 % |
| 2022 | 94.83 % | -213.33 % | -207.98 % |
| 2023 | 83.7 % | -1,300.34 % | -1,280.22 % |
| 2024e | 83.7 % | -2,854.09 % | -2,667.55 % |
| 2025e | 83.7 % | -1,492.75 % | -749.45 % |
| 2026e | 83.7 % | -892.56 % | -317.26 % |
| 2027e | 83.7 % | -995.56 % | -299.57 % |
| 2028e | 83.7 % | -140.84 % | -43.17 % |
| 2029e | 83.7 % | -15.42 % | -6.11 % |
Affimed Aktienanalyse
What does Affimed do?
Affimed NV is a company specializing in the research, development, and marketing of immunotherapies for various types of cancer. The company was founded in 2000 and is headquartered in Heidelberg, Germany. It has been listed on the NASDAQ since 2014. Affimed focuses on developing innovative immunotherapies that adapt the body's immune defense mechanisms. The goal is to stimulate the body's defense against cancer cells. The company divides its work into three areas, reflected in its product range: 1. NK cell engager platform (NKG2D and CD16A engagers) 2. T cell engager platform (tandem fusions and bi- and tri-specifics) 3. ACCEL platform® (antibody-cell conjugates, enhanced loading) Affimed specializes in developing medicines for specific types of cancer with high medical needs, such as certain forms of lymphomas and solid tumors. The company collaborates with other companies to jointly develop and market medications. Its business model is based on partnerships to finance the development and commercialization of medications. In summary, Affimed NV specializes in the development of targeted immunotherapies for combating cancer cells. Its products specifically target NK cells and T cells and aim to promote an effective immune response against certain types of cancer. The company collaborates with other companies to advance therapy development and bring them to market. Affimed NV specializes in the development of immunotherapies for targeted treatment of cancer cells. Affimed ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Affimed's EBIT
Affimed's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Affimed's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Affimed's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Affimed’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Affimed stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Affimed.
How has the EBIT of Affimed developed in recent years?
The EBIT of Affimed has increased by -39.472% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Affimed?
The EBIT of Affimed is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Affimed pay?
Over the past 12 months, Affimed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Affimed is expected to pay a dividend of 0 EUR.
What is the dividend yield of Affimed?
The current dividend yield of Affimed is .
When does Affimed pay dividends?
Affimed pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Affimed?
Affimed paid dividends every year for the past 0 years.
What is the dividend of Affimed?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Affimed located?
Affimed is assigned to the 'Health' sector.
Wann musste ich die Aktien von Affimed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Affimed from 12/19/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/19/2024.
When did Affimed pay the last dividend?
The last dividend was paid out on 12/19/2024.
What was the dividend of Affimed in the year 2023?
In the year 2023, Affimed distributed 0 EUR as dividends.
In which currency does Affimed pay out the dividend?
The dividends of Affimed are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Affimed stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Affimed
Our stock analysis for Affimed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Affimed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
